178 related articles for article (PubMed ID: 3072924)
1. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.
Gisby J; Beale AS
Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
Beale AS; Gisby J
J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
Beale AS; Gisby J
Infection; 1991; 19(2):101-5. PubMed ID: 2050417
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of amoxycillin/clavulanic acid in experimental Bacteroides fragilis/Escherichia coli mixed infections.
Beale AS; Gisby J; Sutherland R
J Antimicrob Chemother; 1988 Apr; 21(4):451-9. PubMed ID: 3288604
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
6. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE
Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of amoxycillin and benzylpenicillin combined with clavulanic acid against Bacteroides fragilis in vitro and in experimentally infected mice.
Dijkmans BA; Vaishnav J; Mattie H
Scand J Infect Dis; 1985; 17(3):311-21. PubMed ID: 3903976
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.
Fuchs PC; Barry AL; Jones RN
J Clin Microbiol; 1988 Jun; 26(6):1246-7. PubMed ID: 3384939
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
Moittie D; Simonet M; Veron M
Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
[TBL] [Abstract][Full Text] [Related]
12. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
Barry AL; Jones RN; Packer RR
J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
[No Abstract] [Full Text] [Related]
13. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
14. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Aronoff SC; Jacobs MR; Johenning S; Yamabe S
Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
[TBL] [Abstract][Full Text] [Related]
15. Increase in the activity of third-generation cephalosporins in combination with clavulanic acid and Sulbactam against Bacteroides fragilis.
Martín MA; Castillo AM; Liebana J; Mesa P; Piedrola G; Gutierrez J
Med Lab Sci; 1990 Jul; 47(3):163-7. PubMed ID: 2402195
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic and clavulanic acid treatment of subcutaneous abscesses caused by Bacteroides fragilis alone or in combination with aerobic bacteria.
Brook I; Coolbaugh JC; Walker RI
J Infect Dis; 1983 Jul; 148(1):156-9. PubMed ID: 6350486
[TBL] [Abstract][Full Text] [Related]
17. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin].
Acar N; Diri MC; Türkyilmaz FR
Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705
[TBL] [Abstract][Full Text] [Related]
18. [Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral formulations as well as in body fluids and tissue homogenates. Comparison of sulbactam, clavulanic acid, ampicillin and amoxicillin].
Wildfeuer A; Räder K
Arzneimittelforschung; 1991 Jan; 41(1):70-3. PubMed ID: 2049115
[TBL] [Abstract][Full Text] [Related]
19. Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus.
Heilmann F
Infection; 1993; 21(3):187-90. PubMed ID: 8365818
[TBL] [Abstract][Full Text] [Related]
20. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
Brook I
J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
